Table 1.

Patient characteristics

BRAFV600E mutated PDO	Gender	Confirmation of BRAFV600E mutation	Confirmation of BRAFV600E mutation*3	MMR-status*4	Histology	Grading	Tumor location	Origin of the cohort	Organ of origin of the PDO	Tumor stage at the time of establishment	Sites of metastasis
HCT153	F	V600E*1	V600E	dMMR	tubular	NA	right	Japan	colon	IV	multiple LN
							(transverse)
HCT156	F	V600E*1	V600E	dMMR	tubular	NA	right	Japan	colon	IIIb	NA
							(transverse)
HCT161	F	V600E*1	V600E	dMMR	poorly differentiated	G3	right	Japan	colon	II	NA
							(transverse)
HCT162	F	V600E*1	V600E	dMMR	tubular	NA	right	Japan	colon	IV	liver
							(cecum)
HCT166	F	V600E*1	V600E	dMMR	tubular	NA	right	Japan	colon	IIIa	NA
							(ascending)
HCT178	F	NA	V600E	dMMR	poorly differentiated	G3	right	Japan	colon	III	NA
							(cecum)
OT212	F	V600E*2	V600E	pMMR	poorly differentiated	G3	right	Berlin	colon	IV	NA
							(ascending)
OT261	F	V600E*2	V600E	dMMR	tubular	G1	right	Berlin	colon	I	NA
							(ascending)
M2	F	V600E*2	V600E	pMMR	mucinous	G3	right	Berlin	liver	IV	liver
							(cecum)
ICP_CRC_01	M	V600E*2	V600E	pMMR	mucinous	NA	right	Berlin	bronchial LN	IV	lung, LN, liver, peritoneum
							(transverse)

HCT human cancer tissue, ICP informative Charite patient, IHC immunohistochemistry, LN lymph node, M Male, dMMR deficient DNA mismatch repair, pMMR proficient Mismatch Repair, NA not available, OT Oncotrack, PDO patient-derived organoid

^*1 at time of PDO establishment by Sanger Sequencing, *2 at time of PDO establishment by WES, *3 at time of PDO expansion by WES and RNA Seq,

^*4 at time of PDO expansion by IHC, dMMR: deficient DNA mismatch repair, pMMR:Proficient Mismatch Repair; CRC: colorectal cancer; F:Female;